CN103458873B - 用于口服肽递送的脂肪酸酰化的氨基酸 - Google Patents

用于口服肽递送的脂肪酸酰化的氨基酸 Download PDF

Info

Publication number
CN103458873B
CN103458873B CN201280017853.5A CN201280017853A CN103458873B CN 103458873 B CN103458873 B CN 103458873B CN 201280017853 A CN201280017853 A CN 201280017853A CN 103458873 B CN103458873 B CN 103458873B
Authority
CN
China
Prior art keywords
sodium
decanoyl
lauroyl
amino acid
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280017853.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN103458873A (zh
Inventor
F.A.费格
A.马克霍夫
H.霍耶
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of CN103458873A publication Critical patent/CN103458873A/zh
Application granted granted Critical
Publication of CN103458873B publication Critical patent/CN103458873B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201280017853.5A 2011-04-14 2012-04-12 用于口服肽递送的脂肪酸酰化的氨基酸 Expired - Fee Related CN103458873B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11162411.0 2011-04-14
EP11162411 2011-04-14
US201161477719P 2011-04-21 2011-04-21
US61/477719 2011-04-21
PCT/EP2012/056708 WO2012140155A1 (en) 2011-04-14 2012-04-12 Fatty acid acylated amino acids for oral peptide delivery

Publications (2)

Publication Number Publication Date
CN103458873A CN103458873A (zh) 2013-12-18
CN103458873B true CN103458873B (zh) 2016-04-13

Family

ID=44343059

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280017853.5A Expired - Fee Related CN103458873B (zh) 2011-04-14 2012-04-12 用于口服肽递送的脂肪酸酰化的氨基酸

Country Status (5)

Country Link
US (1) US20140056953A1 (cg-RX-API-DMAC10.html)
EP (1) EP2696847A1 (cg-RX-API-DMAC10.html)
JP (1) JP6030630B2 (cg-RX-API-DMAC10.html)
CN (1) CN103458873B (cg-RX-API-DMAC10.html)
WO (1) WO2012140155A1 (cg-RX-API-DMAC10.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014060512A1 (en) * 2012-10-17 2014-04-24 Novo Nordisk Health Care Ag Fatty acid acylated amino acids for growth hormone delivery
WO2014060472A1 (en) * 2012-10-17 2014-04-24 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
JP6285447B2 (ja) * 2012-10-17 2018-02-28 ノヴォ ノルディスク アー／エス 経口ペプチド送達用の脂肪酸アシル化ｄ−アミノ酸
WO2015162195A1 (en) * 2014-04-23 2015-10-29 Novo Nordisk A/S Fatty acid acylated amino acids for oral peptide delivery
DK3006045T3 (en) 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
CN104961687B (zh) * 2015-06-03 2017-07-25 苏州维泰生物技术有限公司 1,2‑二嗪衍生物及其制剂、用途
CN111759823B (zh) * 2015-09-17 2022-12-30 阿赖耶识（上海）生物技术有限公司 一种高稳定的非囊泡型纳米颗粒及其在治疗微生物感染中的应用
EP3359181A1 (en) 2015-10-07 2018-08-15 Cyprumed GmbH Pharmaceutical formulations for the oral delivery of peptide drugs
WO2018065634A1 (en) 2016-10-07 2018-04-12 Cyprumed Gmbh Pharmaceutical compositions for the nasal delivery of peptide or protein drugs
BR112020002804A2 (pt) 2017-08-24 2020-07-28 Novo Nordisk A/S composição farmacêutica líquida, e, kit
TWI751379B (zh) 2017-09-21 2022-01-01 奧孟亞股份有限公司 用於遞送胜肽之藥物組合物
WO2019108739A1 (en) * 2017-11-30 2019-06-06 Dana-Farber Cancer Institute, Inc. Chemical uncouplers of respiration and methods of use thereof
FR3075197B1 (fr) * 2017-12-20 2019-11-15 Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic Nouvelle composition de lipoaminoacides et de diols, le procede pour leur preparation et composition cosmetique ou pharmaceutique en resultant
US20210087250A1 (en) 2018-04-06 2021-03-25 Cyprumed Gmbh Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins
KR102853071B1 (ko) 2019-02-07 2025-09-02 베이진 엘티디 Tlr7 작용제로서의 이미다조[2,1-f][1,2,4]트리아진-4-아민 유도체
WO2022049310A1 (en) 2020-09-07 2022-03-10 Cyprumed Gmbh Improved pharmaceutical formulations of glp-1 receptor agonists
EP4180060A1 (en) 2021-11-15 2023-05-17 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4299057A1 (en) 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
EP4433093A1 (en) 2021-11-15 2024-09-25 Adocia Solid compositions comprising a peptide or a protein and an acylated amino acid
WO2023166179A1 (en) 2022-03-03 2023-09-07 Cyprumed Gmbh Improved oral pharmaceutical formulations of therapeutic peptides and proteins
EP4299071A1 (en) 2022-07-01 2024-01-03 Adocia Compositions comprising a peptide or a protein and an acylated amino acid
CN121001710A (zh) 2022-12-30 2025-11-21 阿尔吉法玛公司 提高口服多肽治疗剂的全身生物利用度的组合物和方法
US12544349B1 (en) 2024-12-30 2026-02-10 Adocia Compositions comprising pemvidutide and an acylated amino acid

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2772168A (en) * 1951-11-28 1956-11-27 Colgate Palmolive Co Fermentable carbohydrate food products
US4258029A (en) * 1979-04-23 1981-03-24 Connaught Laboratories Limited Synthetic adjuvants for stimulation of antigenic responses
US4749694A (en) * 1984-04-26 1988-06-07 Merck & Co., Inc. Novel lysine esters used as absorption
US5270032A (en) * 1990-10-04 1993-12-14 The Research Foundation Of State University Of New York Composition and method for the prevention and treatment of candidiasis
US5498420A (en) * 1991-04-12 1996-03-12 Merz & Co. Gmbh & Co. Stable small particle liposome preparations, their production and use in topical cosmetic, and pharmaceutical compositions
US6624754B1 (en) * 1998-01-20 2003-09-23 Hoffman Resources Llc Personal security and tracking system
FR2767064B1 (fr) * 1997-08-07 1999-11-12 Centre Nat Rech Scient Procede de liberation d'un principe actif contenu dans une emulsion multiple
WO2001035998A1 (en) 1999-11-12 2001-05-25 Pharmaderm Laboratories, Ltd. Compositions for transdermal and transmucosal administration of therapeutic agents
FR2828102B1 (fr) * 2001-03-28 2004-07-09 Ifc Sa Utilisation des lipoaminoacides dans une composition pharmaceutique comme promoteur et systeme disperse a usage pharmaceutique contenant de tels composes
US6951655B2 (en) 2001-10-11 2005-10-04 Imi Biomed, Inc. Pro-micelle pharmaceutical compositions
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
AU2004261353B2 (en) 2003-08-05 2009-12-10 Novo Nordisk A/S Novel insulin derivatives
US20050282756A1 (en) 2004-06-18 2005-12-22 Mehta Nozer M Oral delivery of peptide pharmaceutical compositions
JP4147235B2 (ja) * 2004-09-27 2008-09-10 キヤノン株式会社 吐出用液体、吐出方法、液滴化方法、液体吐出カートリッジ及び吐出装置
CN101541830A (zh) 2006-09-22 2009-09-23 诺沃-诺迪斯克有限公司 蛋白酶抗性的胰岛素类似物
GB0623838D0 (en) * 2006-11-29 2007-01-10 Malvern Cosmeceutics Ltd Novel compositions
EP2514406A1 (en) 2007-06-01 2012-10-24 Novo Nordisk A/S Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
HUE032284T2 (en) 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
CN102227213A (zh) * 2008-11-28 2011-10-26 诺沃—诺迪斯克有限公司 适合于衍生化的胰岛素肽的口服施用的药物组合物
JP5123922B2 (ja) 2009-12-02 2013-01-23 独立行政法人科学技術振興機構 融合糖タンパク質から成るエンベロープを有する逆行性輸送ウィルスベクター系

Also Published As

Publication number Publication date
WO2012140155A1 (en) 2012-10-18
CN103458873A (zh) 2013-12-18
JP2014512366A (ja) 2014-05-22
EP2696847A1 (en) 2014-02-19
US20140056953A1 (en) 2014-02-27
JP6030630B2 (ja) 2016-11-24

Similar Documents

Publication Publication Date Title
CN103458873A (zh) 用于口服肽递送的脂肪酸酰化的氨基酸
JP5908847B2 (ja) インスリンペプチドを経口投与するための医薬組成物
US20110293714A1 (en) Pharmaceutical compositions suitable for oral administration of derivatized insulin peptides
US20110144010A1 (en) Spontaneously Dispersible Preconcentrates Including a Peptide Drug in a Solid or Semisolid Carrier
EP1682091B1 (en) Compositions of lipids and cationic peptides
JP2021520391A (ja) 治療用ペプチド及び治療用タンパク質の経粘膜送達のための薬学的組成物
US20150273069A1 (en) Fatty acid acylated amino acids for oral peptide delivery
JP6285447B2 (ja) 経口ペプチド送達用の脂肪酸アシル化ｄ−アミノ酸
EP4210680A1 (en) Improved pharmaceutical formulations of glp-1 receptor agonists
CN1127350C (zh) 含有环孢菌素的软胶囊制剂
Jirwankar et al. Protection of protein drugs by self-emulsified nanoemulsion against proteolysis
WO2015162195A1 (en) Fatty acid acylated amino acids for oral peptide delivery
US20230241233A1 (en) Oral pharmaceutical compositions comprising lipid conjugates
US20250205312A1 (en) Orally Available Albenatide

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160413

Termination date: 20190412